上市后监督总监
职位描述
工作职责:
This new position of Director, Post Market Surveillance (PMS) is accountable for overall strategy, execution and oversight of all activities associated with complaint handling associated quality management systems, functions and regulatory compliance reporting of Adverse Events (AEs) and Medical Device Reportable (MDRs) throughout the product life cycle for MicroPort Cardiovascular business, globally.
? This key leadership role is to ensure governmental regulatory requirements are met, customer experiences are appropriately logged and investigated to both comply with laws/regulations. This position will facilitate proactive quality and associated improvements in customer experience, as well as to ensure the organization is informed of adverse trending through analysis of complaints for Adverse Events, Medical Device Reportable, including tracking and trending.
? Direct leadership accountability and oversight of activities such as (a) uptake and logging of customer complaints, (b) their proper and thorough investigation and subsequent documentation, (c) statistical tracking and trending and associated evaluation and escalation of adverse customer complaint trends and early identification of new issues (with priority on safety issues), (d) proper evaluation of safety and patient risk through overall administration of a Health Hazard Evaluation (HHE) process, and (e) AE and MDR reporting, and the associated timeliness.
? Assures compliance with regards to AE/MDR with the applicable international regulatory requirements (ie, FDA QSRs, ISO 13485, Japanese MHLW, Brazilian ANVISA, EU MDR) for the company
s products, including medical devices, and combination products. Ensures successful internal and external inspections and audits.
? Ensure timeliness of all complaint handling, adverse events, and medical device reporting activities in accordance to procedures, standards and regulations.
? Responsible and accountable for the compliance of all PMS processes and procedures, associated document and performance metrics.
企业简介
上海微创医疗器械(集团)有限公司为中国领先的医疗器械开发商、制造商及营销商,主要专注于治疗血管疾病及病变的微创介入产品。集团于2010年9月于香港联合交易所上市,股份编号:00853。
集团主要供应心血管器械和其他血管器械以及糖尿病器械,主要产品为第二代钴铬合金药物洗脱支架 Firebird 2。集团还供应其他血管支架,用于治疗身体其他部位的血管疾病及失调。集团亦销售极其细小的颅内支架、用于促进脑血管血液流量的灵活支架以及外科手术中使用的覆膜支架。
微创的产品于中国有逾1,100家医院使用,部分产品出口至中国境外的20多个位于亚太地区(不包括中国)、南美及欧洲的国家。
有冠脉药物支架系统、冠脉金属支架系统、颅内动脉支架系统、腹主动脉瘤和胸主动脉瘤等支撑型人造血管支架、球囊(PTCA)扩张导管、导引导管及其相关附件、胰岛素泵、骨科产品、射频消融电生理导管等医疗器械;它们中绝大多数填补国内空白,被认定为上海市高新技术成果转化项目,达国际先进水平,直接与国外产品竞争,已进入中国各大知名医院,并出口日本、欧洲、拉美等国家与地区,具有一定的品牌知名度和市场占有率。
热门区域招聘: 重庆 北京 上海 浙江 江苏 广东 山东 湖南 安徽 河北
上海招聘企业: 百进冠合(海南) 医疗科技有限公司 上海华茂药业有限公司 上海信谊药厂有限公司 上海强生制药 欧姆龙健康医疗(中国)有限公司 青海瑞成药业(集团)有限公司 上海交通大学医学院附属瑞金医院 复旦大学附属中山医院 上海复星医药 上海医药集团
职位发布日期: 2019-05-16